The Latest News from Health GAP

Dedicated to eliminating barriers to global access to affordable life-sustaining medications for people living with HIV/AIDS. 

Gilead’s Hepatitis C Medicines License

Troubling Territorial Exclusions,  Illusory Exceptions, and Tiered Pricing Policy Fracture Global Access 

by Professor Brook K. Baker, Northeastern U. School of Law, Senior Policy Analyst Health GAP 

Trade law expert Brook Baker analyzes Gilead's Hepatitis C medicines license and its impacts on access around the world.

"Gilead has just announced and released the text of its license on two direct-acting oral antivirals (DAAs) used to treat hepatitis C virus (HCV) infections, sofosbuvir (Sovaldi®) and ledipasvir. The License allows seven Indian generic companies – Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. – to manufacture, distribute and sell the individual products and a combination pill of the two products in a subset of 91 low- and middle-income countries (see list attached)."

Read the full policy analysis.

Ugandan and International groups call for urgent action by the World Bank to fight discrimination in Uganda's health sector 

Ugandan and International groups today released a letter to World Bank Executive Director Dr. Jim Kim calling for urgent action to address pervasive discrimination in the health sector, especially for LGBTI communities. The World Bank suspended a $90 million loan to Uganda's health sector when the President signed the Anti Homosexuality Act into law. While this anti gay law was recently overturned, discrimination is still alive and well, and is undermining access to lifesaving health services. The organizations are calling for corrective action by the Government of Uganda--before the loan is restarted.

Read the statement [HERE] and the letter [HERE].

New Health GAP analysis published on emboldening the fight to win the end of AIDS--and combatting austerity
Asia Russell's chapter "Funding the fight to end the AIDS epidemic: instructions from a time of austerity" was published as a in the new 2014 issue of AIDS Today, released at an International HIV/AIDS Alliance event at the London School of Economics last week. 
Health GAP is proud to be part of the first edition of The Alliance's new biennial publication presenting the global state of the civil society response to AIDS. 
In Russell's chapter, she describes the untenable contradiction civil society is faced with: the possibility that communities can secure massive gains in saving lives and halting new HIV infections based on aggressive scale up of evidence based interventions and defense and promotion of human rights, while in reality budget cuts are leaving life saving programs running on empty. 
Confronting this political doublespeak and winning the resources to seize this promise requires emboldened and dauntless activism, according to Russell. Read Health GAP's prescription for action--and the roadmap for urgently needed progress--here